NCT00446368

Safety Study of RAD001 to Treat Patients With Metastatic Kidney Cancer

Phase II Study of RAD001 (Everolimus) in Patient's With Metastatic Renal Cell Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 66 (actual)
• Sponsor: The Methodist Hospital Research Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Patients with metastatic renal cell cancer will be enrolled to receive RAD001 to determine whether the use of RAD001 will result in an improvement in the time to tumor progression.

Detailed description

Patients with metastatic renal cell cancer will be enrolled in the study if all eligibility criteria are met and they agree to participate. The participant will take RAD001 (Everolimus) 10mg by mouth once a day. During the first cycle, they will have blood work done once a week (4 weeks). On cycles thereafter they will have blood work on days 7 and 21. Once a month, the patient will have a chest x-ray. Every 8 weeks the patient will have a CT scan of the chest, abdomen and pelvis. If clinically indicated, additional tests will be done.

Conditions

• Carcinoma, Renal Cell

Interventions

Type	Name	Description
DRUG	RAD001	Participant will take RAD001 (Everolimus) 10mg by mouth once a day.

Timeline

• Start date: 2005-05-01
• Primary completion: 2008-09-01
• Completion: 2008-10-01
• First posted: 2007-03-12
• Last updated: 2016-03-17

Locations

1 site across 1 country: United States